Bone Therapeutics, the Belgium-based bone cell therapy company focused on orthopaedics and bone diseases, has elected a new Chairman of the Board of Directors, while the previous chairman will continue as a Non-Executive Director.

Steve Swinson has been selected to to replace Michel Helbig, who has stood down as Chairman.

Bone Therapeutics has added Dirk Dembski to the Board, as a Non-Executive Director. The appointment of Dirk, an experienced executive with expertise in orthopaedics and biotechnology and experience in sales, marketing, business development and medical education for global life sciences companies, complements the recent appointments of Steve Swinson and Damian Marron, who both joined the Bone Therapeutics Board in May, the company pointed out.

Bone Therapeutics said that these appointments “significantly increase” the breadth of specialist orthopaedic and regenerative therapy expertise at the company and will help support the new management team, led by Chief Executive Thomas Lienard.

Marc Nolet de Brauwere van Steeland, stepped down as a Non-Executive Director on June 30, having served on the Bone Therapeutics Board since 2015.

Thomas Lienard, Chief Executive of Bone Therapeutics, said that with the election of Steve Swinson as Chairman, and the appointments of Dirk Dembski and Damian Marron, the company will get a world-leading Board, as it approaches critical inflection points for its allogeneic cell therapy platform. “Our new Board members bring a unique and highly complementary set of skills and expertise in the development and commercialisation of orthopaedic and cell therapy products.”

Steve Swinson, Chairman of Bone Therapeutics, said that Bone Therapeutics is the most advanced company in regenerative therapies for bone diseases. He said: “I believe (the company) has the potential to transform medical practice in this field. I hope to be able to apply my deep experience in medical technology to support Thomas Lienard and his team, alongside my colleagues on the Board, as we move this key product platform towards commercialization.”

Dirk Dembski added: “I feel my previous experience and expertise wil be invaluable to Bone Therapeutics as it develops into a commercially ready company. I look forward to working with Steve and the rest of the Board to help steer the company as it brings its exciting technologies to market.”